Clinically Detected Nodal Metastases Upon Admission Based on T Stage
| Primary Site | T Stage |
N0, % |
N1, % |
N2-N3, % |
| Oral tongue | T1 |
86 |
10 |
4 |
T2 |
70 |
19 |
11 |
|
T3 |
52 |
16 |
31 |
|
T4 |
24 |
10 |
66 |
|
| Floor of mouth | T1 |
89 |
9 |
2 |
T2 |
71 |
18 |
10 |
|
T3 |
56 |
20 |
24 |
|
T4 |
46 |
10 |
43 |
|
| Retromolar trigone/anterior tonsillar pillar | T1 |
88 |
2 |
9 |
T2 |
62 |
18 |
20 |
|
T3 |
46 |
21 |
33 |
|
T4 |
32 |
18 |
50 |
|
| Soft palate | T1 |
92 |
0 |
8 |
T2 |
64 |
12 |
24 |
|
T3 |
35 |
26 |
39 |
|
T4 |
33 |
11 |
56 |
|
| Tonsillar fossa | T1 |
30 |
41 |
30 |
T2 |
32 |
14 |
54 |
|
T3 |
30 |
18 |
52 |
|
T4 |
10 |
13 |
76 |
|
| Base of tongue | T1 |
30 |
15 |
55 |
T2 |
29 |
14 |
56 |
|
T3 |
26 |
23 |
52 |
|
T4 |
16 |
8 |
76 |
|
| Oropharyngeal walls | T1 |
75 |
0 |
25 |
T2 |
70 |
10 |
20 |
|
T3 |
33 |
22 |
44 |
|
T4 |
24 |
24 |
52 |
|
| Supraglottic larynx | T1 |
61 |
10 |
29 |
T2 |
58 |
16 |
26 |
|
T3 |
36 |
25 |
40 |
|
T4 |
41 |
18 |
41 |
|
| Hypopharynx | T1 |
37 |
21 |
42 |
T2 |
30 |
20 |
49 |
|
T3 |
21 |
26 |
54 |
|
T4 |
26 |
15 |
58 |
|
| Nasopharynx | T1 |
8 |
11 |
82 |
T2 |
16 |
12 |
72 |
|
T3 |
12 |
9 |
80 |
|
T4 |
17 |
6 |
78 |
| Clinical Neck Stage | |||||
| Primary Site | N0 Neck |
N+† Neck |
Overall |
||
| Nasopharynx | 2/5 (40%) |
12/14 (86%) |
74% |
||
| Pharyngeal wall | 6/37 (16%) |
12/56 (21%) |
19% |
||
| Soft palate | 1/21 (5%) |
6/32 (19%) |
13% |
||
| Tonsillar region | 2/56 (4%) |
14/120 (12%) |
9% |
||
| Pyriform sinus or postcricoid area | 0/55 (0%) |
7/81 (9%) |
5% |
||
| Base of tongue | 0/31 (0%) |
5/90 (6%) |
4% |
||
| Supraglottic larynx | 0/87 (0%) |
4/109 (4%) |
2% |
||
N0 |
||||||||
| Treatment | No Treatment |
Partial Treatment |
Complete Treatment |
N1 |
N2a |
N2b |
N3a |
N3b |
| Irradiation | 0% |
15% |
2% |
15% |
27% |
27% |
38% |
34% |
| Surgery | 55% |
35% |
7% |
11% |
8% |
23% |
42% |
41% |
| Combined | – |
20% |
0% |
0% |
0% |
0% |
23% |
25% |
Five-Year Rate of Neck Control by 1983 AJCC Stage and Treatment (459 Patients; 593 Heminecks)
| Radiotherapy Alone | Radiotherapy Plus Neck Dissection |
||||
| Stage | No. of Heminecks |
Control | No. of Heminecks |
Control | Significance |
| N1 | 215 |
86% |
38 |
93% |
P = .28 |
| N2a | 29 | 79% |
24 |
68% |
P = .6 |
| N2b | 138 |
70% |
80 |
91% |
P <.01 |
| N3a | 29 |
33% |
40 |
69% |
P <.01 |
Stage |
|||||
| Treatment | N0 |
N1 |
N2a |
N2b |
N3a |
| Irradiation | 4% |
2% |
9% |
7% |
0% |
| Surgery | 25% |
17% |
23% |
43% |
33% |
| Combined | 0% |
0% |
0% |
11% |
0% |
Metastatic Cervical Lymph Nodes, Unknown Primary Site 3-Year Disease-Free Absolute Survival Rates
Type of Treatment |
|||
| Stage | Surgery |
Radiation Therapy |
Combination Therapy |
| NX | 31/39 (79%) |
8/9 (89%) |
3/3 (100%) |
| N1 | 4/6 (67%) |
1/3 (33%) |
1/3 (33%) |
| N2 | 10/22 (45%) |
3/4 (75%) |
5/9 (55%) |
| N3 | 14/37 (38%) |
13/36 (36%) |
4/13 (31%) |
| Total | 59/104* (57%) |
25/52† (48%) |
13/28† (46%) |